THE CYTOGENETIC SCENARIO OF CHRONIC MYELOID-LEUKEMIA

被引:141
|
作者
MITELMAN, F
机构
[1] Department of Clinical Genetics, University Hospital, S-221
关键词
CYTOGENETICS; KARYOTYPE; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION;
D O I
10.3109/10428199309047856
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Philadelphia chromosome (Ph), i.e., the reciprocal translocation t(9;22)(q34;q11), is found with great specificity in bone marrow cells from patients with chronic myeloid leukemia (CML). Variant Ph-producing translocations, seen in 5-10% of all patients, are all complex and involve the same molecular rearrangement as the regular t(9;22). Patients with classic and variant Ph-producing translocations are clinically and hematologically identical, and as a group differ from Ph-negative CML patients. In all patient groups, the occurrence of additional chromosome changes is an ominous sign indicating that disease progression is imminent. The chromosome changes occurring in excess of the Ph in CML are clearly nonrandom and two pathways of cytogenetic evolution may be distinguished. Major route changes comprise trisomy 8, i(17q), trisomy 19, and an extra Ph; totally, 71% of Ph-positive CML patients have at least one of these four major route changes. Six minor route changes, including five numerical abnormalities (- 7, - 17, + 17, + 21, and - Y) but also one structural aberration, t(3;21) (q26;q22), have been identified. At least one of these changes is found in 15% of all Ph-positive CML cases. Altogether, the four major route aberrations and the six minor route changes are present as part of the clonal evolution in 86% of CML with cytogenetic abnormalities in addition to the Ph chromosome.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 50 条
  • [1] Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays
    Bennour, Ayda
    Saad, Ali
    Sennana, Halima
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 263 - 274
  • [2] APPROACHES TO THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA
    SAVAGE, DG
    GOLDMAN, JM
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1994, 60 (01) : 1 - 21
  • [3] REGULATION OF GROWTH IN CHRONIC MYELOID-LEUKEMIA
    GORDON, MY
    LEUKEMIA & LYMPHOMA, 1993, 11 : 75 - 79
  • [4] THE NEUTROPHIL GRANULOCYTE IN CHRONIC MYELOID-LEUKEMIA
    CARULLI, G
    HAEMATOLOGIA, 1993, 25 (01) : 35 - 55
  • [5] CHRONIC MYELOID-LEUKEMIA AS A PARADIGM FOR ONCOGENESIS
    PINKERTON, PH
    DUBE, ID
    DIAGNOSTIC ONCOLOGY, 1991, 1 (05): : 288 - 297
  • [6] CYTOGENETIC EVENTS AFTER BONE-MARROW TRANSPLANTATION FOR PHILADELPHIA-CHROMOSOME POSITIVE CHRONIC MYELOID-LEUKEMIA
    ZACCARIA, A
    ROSTI, G
    TESTONI, N
    SANTUCCI, MA
    TASSINARI, A
    CELSO, B
    BUZZI, M
    MIGGIANO, MC
    TURA, S
    LEUKEMIA RESEARCH, 1991, 15 (05) : 289 - 296
  • [7] FURTHER EVIDENCE FOR THE MOLECULAR HETEROGENEITY OF CHRONIC MYELOID-LEUKEMIA
    HERNANDEZ, A
    CORRAL, L
    MUNIZ, A
    ALAEZ, C
    ESPINOSA, E
    MARTINEZ, G
    HERNANDEZ, P
    ANNALS OF HEMATOLOGY, 1991, 62 (06) : 217 - 220
  • [8] Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco
    Benchikh, Sara
    Charlene, Soro Somda Georgina
    Bousfiha, Amale
    Razoki, Lunda
    Aboulfaraj, Jamila
    Zarouf, Latifa
    El Hamouchi, Adil
    Malki, Abderrahim
    Nassereddine, Sanaa
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 2765 - 2774
  • [9] CYTOGENETIC CLONAL EVOLUTION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Tarkan-Arguden, Y.
    Ar, M. Cem
    Yilmaz, S.
    Ongoren, S.
    Kuru, D.
    Ure, U.
    Cirakoglu, A.
    Eskazan, A. E.
    Guven, G. S.
    Cetin, G.
    Purisa, S.
    Baslar, Z.
    Deviren, A.
    Aydin, Y.
    Hacihanefioglu, S.
    Ferhanoglu, B.
    Tuzuner, N.
    Ulku, B.
    Soysal, T.
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2009, 23 (04) : 1515 - 1520
  • [10] A PROPOSED STAGING SYSTEM FOR CHRONIC MYELOID-LEUKEMIA
    ROSS, DW
    BRUNNING, RD
    KANTARJIAN, HM
    KOEFFLER, HP
    OZER, H
    CANCER, 1993, 71 (11) : 3788 - 3791